Export Citation
Export Citation
Olier, I, Sirker, A, Hildick-Smith, DJR, Kinnaird, T, Ludman, P, de Belder, MA, Baumbach, A, Byrne, J, Rashid, M, Curzen, N, Mamas, MA and British Cardiovascular Intervention Society and the National Ins (2018) Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention. Heart. ISSN 1355-6037
Preview |
Text
heartjnl-final_version_deposit.pdf - Accepted Version Download (4MB) | Preview |
Abstract
OBJECTIVES: Prasugrel and ticagrelor both reduce ischaemic endpoints in high-risk acute coronary syndromes, compared with clopidogrel. However, comparative outcomes of these two newer drugs in the context of primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) remains unclear. We sought to examine this question using the British Cardiovascular Interventional Society national database in patients undergoing primary PCI for STEMI. METHODS: Data from January 2007 to December 2014 were used to compare use of P2Y12 antiplatelet drugs in primary PCI in >89 000 patients. Statistical modelling, involving propensity matching, multivariate logistic regression (MLR) and proportional hazards modelling, was used to study the association of different antiplatelet drug use with all-cause mortality. RESULTS: In our main MLR analysis, prasugrel was associated with significantly lower mortality than clopidogrel at both 30 days (OR 0.87, 95% CI 0.78 to 0.97, P=0.014) and 1 year (OR 0.89, 95% CI 0.82 to 0.97, P=0.011) post PCI. Ticagrelor was not associated with any significant differences in mortality compared with clopidogrel at either 30 days (OR 1.07, 95% CI 0.95 to 1.21, P=0.237) or 1 year (OR 1.058, 95% CI 0.96 to 1.16, P=0.247). Finally, ticagrelor was associated with significantly higher mortality than prasugrel at both time points (30 days OR 1.22, 95% CI 1.03 to 1.44, P=0.020; 1 year OR 1.19 95% CI 1.04 to 1.35, P=0.01). CONCLUSIONS: In a cohort of over 89 000 patients undergoing primary PCI for STEMI in the UK, prasugrel is associated with a lower 30-day and 1-year mortality than clopidogrel and ticagrelor. Given that an adequately powered comparative randomised trial is unlikely to be performed, these data may have implications for routine care.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | 1102 Cardiovascular Medicine And Haematology |
| Subjects: | Q Science > QA Mathematics R Medicine > R Medicine (General) |
| Divisions: | Applied Mathematics (merged with Comp Sci 10 Aug 20) |
| Publisher: | BMJ Publishing Group |
| Related URLs: | |
| Date of acceptance: | 7 January 2018 |
| Date of first compliant Open Access: | 18 September 2018 |
| Date Deposited: | 18 Sep 2018 10:30 |
| Last Modified: | 04 Sep 2021 02:30 |
| DOI or ID number: | 10.1136/heartjnl-2017-312366 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/9243 |
 |
View Item |